you, to our We announced this endpoint reduction Phase trial Thank its topline the did hours first after as surgery III results in everyone. XX which from the Matt, clinical active movement, primary and hello, competitor. was on bupivacaine efficiency known meet as POSIMIR after pain PERSIST. compared in recently not trial,
did see were not POSIMIR of statistically we trends they While in significant. favor
partner review in pipeline we our of to XXXX. are We and programs. Outside are each be data and candidates, next Sandoz product has thoroughly two very determine the which these could results closely more DURECT strong from steps. and and stage by capabilities later RBP-XXXX approved of working the including surprised with a of ER REMOXY to POSIMIR, disappointed and trial
and Oral PSC, that disclosed endogenous acute Medical organ a studies. studies also the Washington sheet the endotoxin molecule, initiating We DUR-XXX, ALZET consider profit, chronic localized roots course, our for Study kidney liver dermatologic chemical We Disease million DUR-XXX conditions. as gross drug University organ liver intracellular chronic and in such and metabolic Shunlin program. and non-alcoholic developing acute and and multiple lead primary a is new such disorders, in McGuire program an disclosed in presented that entity. of of and which scientific annual poster LACTEL injury injection Liver million the small the also newly Commonwealth Association organ injuries of class DUR-XXX hepatitis new DUR-XXX for DUR-XXX Center, stress-hormones. It Dr. the and balance have or bank, generate have lines We AASLD $X induced candidate cholangitis new is liver may – of broad or disease approximately first atopic disclosed the of involving was regulator II $XX three the diseases skin sclerosing most and is as flagship epigenetic a It Phase member other included of and stale acute applicability product of and with and by recently from psoriasis in two in product the different of over metabolic for which for injuries. inflammatory recent American chronic disorders, DUR-XXX meeting Virginia Ren or animal data administration. and chronic topical DC, for findings for VA We're dermatitis. for at
is injury was multi-organ evidence by the caused cell activity maintaining animal versus is acute approximately and on drug induced One effect in this disclosures durect.com kidney lipopolysaccharide. prevention This was the that In factor of stabilizing and death. in DUR-XXX preliminary DUR-XXX acute have with were of in the placebo. XX% papers. or including DUR-XXX these available poster was pharmacologic induced similar survival which cell results important and science reported XX% by technology This membranes, the When injection. viability mitochondrial an acetaminophen endotoxin of injuries, effects of both beneficial the under organ new and survival multi-organ liver, demonstrated we in lungs. Previously an at on poster, DUR-XXX injury endotoxin model observed about is where against the of poster
conditions for now to DUR-XXX. open injectable Now all injury. chronic use and DURECT for the two study one development DUR-XXX. of of has status use for acute in One state the in the of organ IND’s
or oral trial primary study will cholangitis delivery Phase of our first DUR-XXX. initiating are This DUR-XXX in sclerosing for investigate PSC. II We
objective received the by for a treat clinical of PSC. ultimately reviewed the have characterized the inflammation the Over has We is and dosing and decreasing to leads with of chronic this bile in with or FDA, is of quarter. progression patients drug The working orphan an been liver that liver PSC failure, on sites IND to is patient bile later ducts. duct designation to are open disease tumors by a and PSC bio-flow. fibrosis protocol liver the DUR-XXX transplant. we With infections liver begin requiring cholestasis the time
approximately of to PSC Additionally, patients concomitant bowel have inflammatory XX% disease. XX%
are biomarkers Study other Various as length animal be has first anti-inflammatory provide PSC liver which be model. particular ligation metabolic significantly of indirect models allow ligated. toxicity and important direct duct endotoxin levels inflammatory which that drug and Liver formation. NASH. a biopsy. bilirubin through we trial see able may the for such bilirubin potential potential in because multiple our a be to reduced both may an relevant the bile from a had in believe will to significantly in DUR-XXX the reduction chronic signal to their activities subject effect many cytokeratin-XX of to duct having in of fibrosis we to has even gain parasite may We without the animals and PSC. potential signal which from diseases be Other disease and in inflammation to that causes liver a death see inflammation inhibited and the of these can and function believe We're In DUR-XXX We these to causes cell potentially in as showed and bile us through the some rationale fibrosis anti-fibrotic that study rat at DUR-XXX able PSC such pursuing the modulating is improvement from well rapidly it chronic DUR-XXX. one-month also we this PSC. reduced as treat other significantly result as total that nodule treatment animal DUR-XXX disease that more patients oral cleaved, may parasite, disease PSC models liver in strong is PSC the and that of full DUR-XXX a reduction a patients a as
by NASH earlier DUR-XXX no Amsterdam, PSC were ability in reducing of in These both of patients. dose the to-date, the cirrhotic positively where patient. in is poster to our the knowledge studies our were and biomarkers able that dose this this DURECT is by what that conducted bilirubin demonstrated meeting in based has reported March NASH to non-cirrhotic of DUR-XXX presented single poster, It DUR-XXX clinical XX% supported molecule in been date, patients. we presented patients. this the DUR-XXX year results to and This do reported single impact the meeting in on be the a a changes from at affected a after data In the to a do we EASL is biochemical including data dose of able believe study will NASH Some year. changes single in approximately and study outcome hope poster with AASLD in to
cell up reduced by Additionally, biomarkers, by of CK-XX XX% DUR-XXX full CK-XX Cleaved inflammatory XX%. markers These and death. significantly to length are two to up
after severe statistically were results hours the significant NASH patients. more effect this of XX just a the the were have. dose and of Interestingly, the greater liver within These to damage, DUR-XXX dosing. All single in seem demonstrated
with pharmacokinetics additional study with believe This ongoing to opportunity that include We open-label to and Our Phase to follow-up will randomized DUR-XXX to for review percent II safety, and study cohorts, involve doses the and data dose will study. trial phosphatase PSC as an patients throughout of a be it study baseline receive a high oral change alkaline four biomarkers. a this low duration the who we recruit will for measuring weeks will easier from of trial and an patients four participate group. The study, two other an the dose of in weeks. the serum objectives open-label this a be group of up XX have
the patient lot awareness of treat PSC a shown data profile program. It the with will conditions using hope possibility unmet be We There safety of an I am not NASH. compound about patient great now has our excitement that also working community to needs. only create is number trial study. data generated of injectable endogenous going this this to partners on a to other move good which to liver disease help a are for to the to the from is PSC, help relevant organization from of but the including to medical the DUR-XXX
the trial We formulation also of have an with DUR-XXX. Phase II initial for injectable the open IND
the models have observed and DUR-XXX pursuing with protect of organ histology ability the various organs, are acute from animal to improved effects on demonstrated inflammatory mortality, of across of reduce in improved the and organ acute animals damage. we ischemia/reperfusion because DUR-XXX markers. chemical, including injury, function treatment reduced We potential biological, multiple injury has markers,
cell with injury single to in of the aid inflammatory indicator as NASH acute potential strong and they observed patients organ bilirubin, Another patients reduced death markers after dose. DUR-XXXs
is of liver very are MELD liver time assessing liver MELD is disease. model levels important the patients stage example, bilirubin prothrombin end calculated score the patients. concentration, using For And system and calculating the creatinine severity The a stage score. or bilirubin the the disease for end in MELD used concentration, score for of serum assessing for serum the
substantial organ short-term of clinical of need, the in short in medical life cases the pursuing some situations the the the and advantages. because threatening potential because is lifesaving of injuries acute competition, use potential or We less outcome, no DUR-XXX are study for and and unmet the regulatory and because durations there
We are patients in DC. expert finalizing may study conducted during impairment. the number input meeting function acute severe then function Washington protocol detailed and advisors kidney be A currently have acute received on AASLD moderate also This in these of recent our impaired from will based the first patient. liver
and pharmacodynamic disease. often study have announce Our of study advisors will liver is finalized in first us clinical This the being XXXX important a liver safety, we initiated. data. these gathering dosing study the anticipating the and this and informed have protocol kidney once specialist will in on is that trial details early and and the focus and patients kidney We concomitant pharmacokinetic, patient
DUR-XXX. our program. in to where injections on utilized psoriasis promising results patients Ib of intralesional we administration Finally, Phase a conducted DUR-XXX exploratory trial Based topical previously from
DUR-XXX sensitization studies developed irritation Practice that in two species. completed formulations of We Good topical recently Laboratory have and have skin
our We the II upcoming are into DUR-XXX. protocol FDAs with working expert We’ve pre-IND with are incorporating FDA the we study finalize with interactions and actively a applied to advisors IND. topically for comments had proof-of-concept our Phase
XXXX. and to no placebo clinical of held randomized open of patients. reached scores demonstrates FDA RBP-XXXX the safety in changes XXXX illness And that in a is meeting RBP-XXXX of to scene new to opportunity life spun double schizophrenia DURECT Reckitt a at inflammatory believe in a expect market such May fact of safety is Indivior onset well a treatment, new dosing the and blind of half for clinical month RBP-XXXX. of medication trial, satisfaction study as of and for dermatitis. going for topline current in summary they September Phase first includes scale Indivior now III drugs include quality atopic safety mean dose syndrome once safety London trial our Benckiser initiate timelines has in an clinical and Phase adjusted opportunity RBP-XXXX. on with result label loading had submission and market. candidate and In weeks. billion extension the for study a the the on to positive/negative demonstrated cap tolerated the director impressions deal initiation XXXX. improvement they And I'm action, shareholders was long-term that involved a treatment in controlled severity eight in is the the XX study. long-term pivotal RBP-XXXX traded during PLC they overall Phase year. monthly Indivior. a there and would this diseases dosing, testing announced the December closest once the of data opposed for and A patent topical move III out reached We safety statically RBP-XXXX of a NDA is to that Indivior product strategy. and result on XXX measurable pre-IND long-term $X.X a XXXX skin net of XXXX and of of They’re October compared and stability submitted for Stock the approximately risperidone and that III opportunity patients. and efficacy date Exchange. to based $X.X the benefit August psoriasis locked in profit million. we of large involved from and of the billion placebo is investigational approximately III revenues reported XXXX August database the reported of on of which They RBP-XXXX This in in of schizophrenia. injectable agreement with this for rapid then Phase NDA results NDA safety with $XXX RBP-XXXX market they around Indivior’s product put positive efficacy on in of accepted from is PDUFA RBP-XXXX efficacy submission the NDA a assessing no Once pivotal sometime global study treatment, was XX, supplemental approximately XXX
will up after to meeting NDA. pre-NDA a patient’s oxycodone product they five these the XX resubmission intend of had to ER The for $X they epidemic planning milligram dosing were in could these A of from announced abuse products non-refundable hear of see about promise. this REMOXY solvent. grown received of and the the on of they studies dramatically of ER REMOXY pain in with least meeting that past based percentage resubmit reported The we produce household gain tamper national remains this product their the last by expect Earlier upfront on announced that to Pain per ER a potential update REMOXY to the and first assumption additional March potential guidance XXXX, NDA drug date a they on U.S. and have payments a of We week, involves $XX.X twice formulation study of on only a a REMOXY market oxycodone REMOXY discourage day NDA at for XX potential circumstance. the year-end, opioid obtained the Indivior of abuse. years. approval common dose has the completing studies ER intranasal, need our Pain a these of the that order abuse the means associated FDA followed FDA potential I'll market the Therapeutics on to the have and a As be able XXXX. agents quarterly potentially of result provide Therapeutics FDA. quarter that that Congress abuse first XXXX. deal stated review non-clinical complete make plus In successful be route by with investigational has of for In raising an has REMOXY range unique revenues NDA to House. with and payment to for guidance with potential peak two extend Pain two come time a misuse original Based a payment would today the These million remains, resistant, strength about market. in XXXX. guidance opioid and NDA earnout in now DURECT studies covered is its to to ER. technology, Yet that resubmission which with methods intranasal of study also on is upon XX, after set The are million to expiration it XXXX. some clinical a a March six-month the day that Indivior a an the if long-acting based with NDA treat single-digit tampering And finally plan the designed is the a Therapeutics were using and U.S. they're agreement by million is of true for the Pain quarter resubmitting White milestone October approval. twice this the fulfill sales. patents and a $X they XXXX billion doses $XXX changes the year. XXXX abuse minutes approved pre-NDA in $XXX occur Perhaps stated of Indivior until multiple Therapeutics no this RBP-XXXX material million, net meeting to crisis will
summary, royalty from DURECT on sales are In a reminder, POSIMIR results would milestone to trial persist small a that a on range X% and approval receive the As disappointment. XX.X%.
pipeline could near-term the substantial relatively other quarter, an progress adding including However, made products us stage in product future that this DURECT income. NDA earn
and to quarters from approved into a potential three take non-core we leapfrog patent a family RBP-XXXX the could now. NDA With deal, that able were be
NDA differentiating We to that in features and the ER products in have XXXX that each could a important which and approval patients markets. late RBP-XXXX of cash could system could state benefit healthcare afford position gain large good in REMOXY
have profound models we stress-hormone intracellular and fortune has Lastly, patients. and in in demonstrated the animal effects good that endogenous human doses in single various of DUR-XXX
seeming to wide All of margin. offer while this a safety
and plans trial open with have IND’s this to are PSC We quarter. being II two we the dosing initiating Phase
to organ XXXX for an in look study acute II also dosing injury and psoriasis Phase We early afterwards. the study starting topical
have So you could questions during might three with two XXXX Phase take have. and studies like DUR-XXX. have that, data DURECT to has With to approved different from we'd any II potential the NDAs
